Snyder Capital Management’s Haemonetics HAE Stock Holding History

Snyder Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-221,279	Closed	-$7.15M	–	71
2015 Q3	$7.15M	Sell	221,279 -538,021	-71%	-$20.2M	0.46%	45
2015 Q2	$31.4M	Sell	759,300 -262,729	-26%	-$11.1M	1.76%	23
2015 Q1	$45.9M	Sell	1,022,029 -129,758	-11%	-$5.42M	2.33%	16
2014 Q4	$43.1M	Buy	1,151,787 +7,100	+0.6%	+$260K	2.27%	17
2014 Q3	$40M	Sell	1,144,687 -152,700	-12%	-$5.45M	2.23%	18
2014 Q2	$45.8M	Buy	1,297,387 +74,840	+6%	+$2.5M	2.12%	19
2014 Q1	$39.8M	Sell	1,222,547 -72,337	-6%	-$2.76M	2.07%	21
2013 Q4	$54.6M	Buy	1,294,884 +34,778	+3%	+$1.43M	2.68%	14
2013 Q3	$50.3M	Buy	1,260,106 +10,260	+0.8%	+$430K	2.61%	15
2013 Q2	$51.7M	Buy	+1,249,846	New	+$50.6M	2.76%	14

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Snyder Capital Management's HAE Position: Q4 2015 in Review

Snyder Capital Management sold out of Haemonetics (HAE) in Q4 2015, closing a stake of 221,279 shares — an estimated $7.15M sold.

Snyder Capital Management first reported a position in HAE in Q2 2013 and held it in 10 quarters. The position peaked at $54.6M in Q4 2013. 164 funds tracked by Wall St. Rank hold HAE as of Q4 2015.

Snyder Capital Management reported no remaining Haemonetics position as of Q4 2015 after selling out during the quarter.
Snyder Capital Management sold 221,279 Haemonetics shares in Q4 2015, an estimated $7.15M.
Snyder Capital Management first reported a position in Haemonetics in Q2 2013 and held it in 10 quarters.
Snyder Capital Management's Haemonetics position peaked at $54.6M in Q4 2013.
164 funds tracked by Wall St. Rank held Haemonetics as of Q4 2015.

Based on Snyder Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.